Sanofi to Acquire Blueprint Medicines to Strengthen Rare Immunological Disease Portfolio
Monday, June 02, 2025
Sanofi has announced plans to acquire Blueprint Medicines.
This acquisition will enhance Sanofi’s position in the immunology space, bringing both a marketed therapy and a promising pipeline of new treatments.
Blueprint’s key asset is Ayvakit/Ayvakyt (avapritinib), a therapy approved in both the United States and Europe. It is currently the only available treatment for both advanced and indolent forms of systemic mastocytosis, a rare condition caused by the accumulation and activation of abnormal mast cells in various organs, including the bone marrow, skin, and gastrointestinal tract.
Blueprint’s established relationships with specialists in allergy, dermatology, and immunology are expected to support the growth of Sanofi’s existing and future immunology portfolio.
Sanofi will acquire Blueprint at $129.00 per share in cash, giving the transaction an equity value of approximately $9.1 billion. Additionally, Blueprint shareholders will receive a contingent value right (CVR), offering potential milestone payments of up to $6 per share, linked to the future progress of BLU-808. Including the CVR, the total equity value of the transaction could reach around $9.5 billion on a fully diluted basis.
Through the deal, Sanofi will also gain access to elenestinib, a next-generation treatment for SM, and BLU-808, an oral KIT inhibitor with the potential to treat a wide range of immunological conditions.
Source: sanofi.com
